SAN FRANCISCO--(BUSINESS WIRE)--Encellin, a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing ...
LAS VEGAS, Dec. 16, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes ...
In a recent article in Scientific Reports, researchers examined the use of single-layer graphene oxide (slGO) nanosheets to enhance the proliferation and osteogenic differentiation of human bone ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results